(Q38168903)

Revision as of 21:00, 7 October 2022 by KrBot (talk | contribs) (‎Set a claim value: title (P1476): Recent progress concerning CpG DNA and its use as a vaccine adjuvant)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

English

Recent progress concerning CpG DNA and its use as a vaccine adjuvant

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

30 June 2019

http://europepmc.org/abstract/PMC/6335645

Recent progress concerning CpG DNA and its use as a vaccine adjuvant (English)

1 reference

Europe PubMed Central

PMC publication ID

30 June 2019

http://europepmc.org/abstract/PMC/6335645

author name string

Hidekazu Shirota

1

1 reference

Europe PubMed Central

PMC publication ID

30 June 2019

http://europepmc.org/abstract/PMC/6335645

Dennis M Klinman

2

1 reference

Europe PubMed Central

PMC publication ID

30 June 2019

http://europepmc.org/abstract/PMC/6335645

language of work or name

1 reference

based on heuristic

inferred from title

publication date

26 November 2013

1 reference

Europe PubMed Central

PMC publication ID

30 June 2019

http://europepmc.org/abstract/PMC/6335645

Expert Review of Vaccines

1 reference

Europe PubMed Central

PMC publication ID

30 June 2019

http://europepmc.org/abstract/PMC/6335645

13

1 reference

Europe PubMed Central

PMC publication ID

30 June 2019

http://europepmc.org/abstract/PMC/6335645

2

1 reference

Europe PubMed Central

PMC publication ID

30 June 2019

http://europepmc.org/abstract/PMC/6335645

299-312

1 reference

Europe PubMed Central

PMC publication ID

30 June 2019

http://europepmc.org/abstract/PMC/6335645

Approaching the asymptote? Evolution and revolution in immunology

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

The dorsoventral regulatory gene cassette spätzle/Toll/cactus controls the potent antifungal response in Drosophila adults

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Defective LPS Signaling in C3H/HeJ and C57BL/10ScCr Mice: Mutations in Tlr4 Gene

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Innate immune recognition

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Toll-like receptor signalling

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Toll-like receptors 2 and 4: initiators of non-septic inflammation in critical care medicine?

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Cutting edge: activation of Toll-like receptor 2 induces a Th2 immune response and promotes experimental asthma

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Toll-like receptor 4 is required for optimal development of Th2 immune responses: role of dendritic cells

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Immunotherapeutic uses of CpG oligodeoxynucleotides

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Plasmacytoid dendritic cells in immunity

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Natural type I interferon-producing cells as a link between innate and adaptive immunity

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

IFN-alpha beta promote priming of antigen-specific CD8+ and CD4+ T lymphocytes by immunostimulatory DNA-based vaccines

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Regulation of murine airway eosinophilia and Th2 cells by antigen-conjugated CpG oligodeoxynucleotides as a novel antigen-specific immunomodulator.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

TLR9 signals after translocating from the ER to CpG DNA in the lysosome

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Intracellular localization of Toll-like receptor 9 prevents recognition of self DNA but facilitates access to viral DNA.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Transmembrane mutations in Toll-like receptor 9 bypass the requirement for ectodomain proteolysis and induce fatal inflammation.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

β-Defensin 2 and 3 promote the uptake of self or CpG DNA, enhance IFN-α production by human plasmacytoid dendritic cells, and promote inflammation

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Proteolytic cleavage in an endolysosomal compartment is required for activation of Toll-like receptor 9

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptor.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Critical role for asparagine endopeptidase in endocytic Toll-like receptor signaling in dendritic cells

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Nucleic acid recognition by Toll-like receptors is coupled to stepwise processing by cathepsins and asparagine endopeptidase.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Strategies for enhancing the immunostimulatory effects of CpG oligodeoxynucleotides

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-alpha induction in plasmacytoid dendritic cells

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Properties regulating the nature of the plasmacytoid dendritic cell response to Toll-like receptor 9 activation

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Toll-like receptor control of the adaptive immune responses

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Cytokines and transcription factors that regulate T helper cell differentiation: new players and new insights.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Interleukin 15-dependent crosstalk between conventional and plasmacytoid dendritic cells is essential for CpG-induced immune activation.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

The reciprocal interaction of NK cells with plasmacytoid or myeloid dendritic cells profoundly affects innate resistance functions.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Long-term effect of primary immunization on subsequent immune responsiveness.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Protective CD8 T cell immunity triggered by CpG-protein conjugates competes with the efficacy of live vaccines

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Novel roles of CpG oligodeoxynucleotides as a leader for the sampling and presentation of CpG-tagged antigen by dendritic cells

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

B cells capturing antigen conjugated with CpG oligodeoxynucleotides induce Th1 cells by elaborating IL-12.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Upregulation of costimulatory molecules induced by lipopolysaccharide and double-stranded RNA occurs by Trif-dependent and Trif-independent pathways

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Global changes in gene expression and synergistic interactions induced by TLR9 and TLR3

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Paired Toll-like receptor agonists enhance vaccine therapy through induction of interleukin-12.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Synergistic activation of innate immunity by double-stranded RNA and CpG DNA promotes enhanced antitumor activity

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Synergy of CpG oligodeoxynucleotide and double-stranded RNA (poly I:C) on nitric oxide induction in chicken peripheral blood monocytes

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition [corrected].

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

CpG Oligodeoxynucleotides Act as Adjuvants that Switch on T Helper 1 (Th1) Immunity

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

The immunogenicity and protective efficacy of bovine herpesvirus 1 glycoprotein D plus Emulsigen are increased by formulation with CpG oligodeoxynucleotides

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

CpG-containing oligodeoxynucleotides, in combination with conventional adjuvants, enhance the magnitude and change the bias of the immune responses to a herpesvirus glycoprotein.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

CpG oligodeoxynucleotide enhances immunity against blood-stage malaria infection in mice parenterally immunized with a yeast-expressed 19 kDa carboxyl-terminal fragment of Plasmodium yoelii merozoite surface protein-1 (MSP1(19)) formulated in oil-ba

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

CpG oligodeoxynucleotide and Montanide ISA 51 adjuvant combination enhanced the protective efficacy of a subunit malaria vaccine

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Current progress in the development of the B subunits of cholera toxin and Escherichia coli heat-labile enterotoxin as carriers for the oral delivery of heterologous antigens and epitopes

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Mucosal adjuvants and long-term memory development with special focus on CTA1-DD and other ADP-ribosylating toxins

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Comparison of intranasal and transcutaneous immunization for induction of protective immunity against Chlamydia muridarum respiratory tract infection

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Mucosal immunization with helicobacter, CpG DNA, and cholera toxin is protective

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

The adjuvant effect of CpG oligodeoxynucleotide linked to the non-toxic B subunit of cholera toxin for induction of immunity against H. pylori in mice

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Prophylactic administration of bacterially derived immunomodulators improves the outcome of influenza virus infection in a murine model

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Adjuvant requirement for successful immunization with recombinant derivatives of Plasmodium vivax merozoite surface protein-1 delivered via the intranasal route

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Therapeutic dendritic cell vaccination with Ag coupled to cholera toxin in combination with intratumoural CpG injection leads to complete tumour eradication in mice bearing HPV 16 expressing tumours

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Intranasal vaccinations with the trans-sialidase antigen plus CpG Adjuvant induce mucosal immunity protective against conjunctival Trypanosoma cruzi challenges.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Mucosal administration of CpG oligodeoxynucleotide elicits strong CC and CXC chemokine responses in the vagina and serves as a potent Th1-tilting adjuvant for recombinant gD2 protein vaccination against genital herpes

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Cost-effectiveness of hepatitis B vaccination using HEPLISAV™ in selected adult populations compared to Engerix-B® vaccine

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

The potential of 1018 ISS adjuvant in hepatitis B vaccines: HEPLISAV™ review

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine: a review of HEPLISAV™ safety and efficacy

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

CpG oligonucleotides improve the protective immune response induced by the anthrax vaccination of rhesus macaques

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Systemic but not mucosal immunity induced by AVA prevents inhalational anthrax

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

CpG oligodeoxynucleotides adsorbed onto polylactide-co-glycolide microparticles improve the immunogenicity and protective activity of the licensed anthrax vaccine

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Effect of CpG oligonucleotides on vaccine-induced B cell memory

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Randomized, double-blind, placebo-controlled, safety and immunogenicity study of 4 formulations of Anthrax Vaccine Adsorbed plus CPG 7909 (AV7909) in healthy adult volunteers.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Marked enhancement of the immune response to BioThrax® (Anthrax Vaccine Adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel with CPG 7909, using two different formulations and dosing intervals

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Impact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1/Alhydrogel+CPG 7909.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in malaria naïve adults

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Assessment of clinical efficacy of CYT003-QbG10 in patients with allergic rhinoconjunctivitis: a phase IIb study

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Vaccination with a recombinant protein encoding the tumor-specific antigen NY-ESO-1 elicits an A2/157-165-specific CTL repertoire structurally distinct and of reduced tumor reactivity than that elicited by spontaneous immune responses to NY-ESO-1-ex

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8⁺ T-cell responses in melanoma patients

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Cellular immunity in breast cancer patients completing taxane treatment

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

The Suppressive Tumor Microenvironment: A Challenge in Cancer Immunotherapy

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Myeloid-derived suppressor cells: linking inflammation and cancer

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Intratumoral injection of CpG oligonucleotides induces the differentiation and reduces the immunosuppressive activity of myeloid-derived suppressor cells

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Therapeutic potential of Toll-like receptor 9 activation

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Pulmonary and cutaneous vasculitis following hepatitis B vaccination

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Induction of immune-mediated glomerulonephritis in normal mice immunized with bacterial DNA.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Theoretical and experimental approaches to generalized autoimmunity

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Induction of cross-reactive anti-dsDNA antibodies in preautoimmune NZB/NZW mice by immunization with bacterial DNA.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Toll-like receptor 9 in murine lupus: more friend than foe!

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Therapeutic administration of a synthetic CpG oligodeoxynucleotide triggers formation of anti-CpG antibodies

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

CpG motifs in bacterial DNA trigger direct B-cell activation

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Liposomes to target the lymphatics by subcutaneous administration

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Enhanced hepatitis C virus NS3 specific Th1 immune responses induced by co-delivery of protein antigen and CpG with cationic liposomes

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Systemic administration of LPD prepared with CpG oligonucleotides inhibits the growth of established pulmonary metastases by stimulating innate and acquired antitumor immune responses

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Multifunctional nanorods for gene delivery

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Induction of systemic and mucosal immune responses by intranasal administration of alginate microspheres encapsulated with tetanus toxoid and CpG-ODN.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Alginate-coated chitosan nanogel capacity to modulate the effect of TLR ligands on blood dendritic cells

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

The effect of CTAB concentration in cationic PLG microparticles on DNA adsorption and in vivo performance

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Enhancement of immune responses by co-delivery of a CpG oligodeoxynucleotide and tetanus toxoid in biodegradable nanospheres

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

PLGA-polymer encapsulating tumor antigen and CpG DNA administered into the tumor microenvironment elicits a systemic antigen-specific IFN-γ response and enhances survival

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Efficient In vivo Priming by Vaccination with Recombinant NY-ESO-1 Protein and CpG in Antigen Naïve Prostate Cancer Patients

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Monophosphoryl Lipid A (MPL) as an Adjuvant for Anti-Cancer Vaccines: Clinical Results

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 (Toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Immune response by nasal delivery of hepatitis B surface antigen and codelivery of a CpG ODN in alginate coated chitosan nanoparticles

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.863715

21 January 2018

Regulation of T-helper type 2 cell and airway eosinophilia by transmucosal coadministration of antigen and oligodeoxynucleotides containing CpG motifs

1 reference

https://pubmed.ncbi.nlm.nih.gov/24308579

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sterically Stabilized Cationic Liposomes Improve the Uptake and Immunostimulatory Activity of CpG Oligonucleotides

1 reference

https://pubmed.ncbi.nlm.nih.gov/24308579

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/24308579

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant

1 reference

https://pubmed.ncbi.nlm.nih.gov/24308579

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effective induction of CD8+ T-cell response using CpG oligodeoxynucleotides and HER-2/neu-derived peptide co-encapsulated in liposomes

1 reference

https://pubmed.ncbi.nlm.nih.gov/24308579

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine

1 reference

https://pubmed.ncbi.nlm.nih.gov/24308579

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist

1 reference

https://pubmed.ncbi.nlm.nih.gov/24308579

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/24308579

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunotherapy and chemotherapy--a practical partnership

1 reference

https://pubmed.ncbi.nlm.nih.gov/24308579

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/24308579

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The role of CpG ODN in enhancement of immune response and protection in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63) encapsulated in cationic liposome.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24308579

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/24308579

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dynavax trial halted

1 reference

https://pubmed.ncbi.nlm.nih.gov/24308579

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Local administration of PF-3512676 CpG-B instigates tumor-specific CD8+ T-cell reactivity in melanoma patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/24308579

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CpG oligodeoxynucleotides alter lymphocyte and dendritic cell trafficking in humans

1 reference

https://pubmed.ncbi.nlm.nih.gov/24308579

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

BCR-mediated uptake of antigen linked to TLR9 ligand stimulates B-cell proliferation and antigen-specific plasma cell formation

1 reference

https://pubmed.ncbi.nlm.nih.gov/24308579

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunization against leishmaniasis by PLGA nanospheres encapsulated with autoclaved Leishmania major (ALM) and CpG-ODN

1 reference

https://pubmed.ncbi.nlm.nih.gov/24308579

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CpG blocks immunosuppression by myeloid-derived suppressor cells in tumor-bearing mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/24308579

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CpG-conjugated apoptotic tumor cells elicit potent tumor-specific immunity

1 reference

https://pubmed.ncbi.nlm.nih.gov/24308579

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cholera toxin - a foe & a friend.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24308579

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nanoparticles encapsulating hepatitis B virus cytosine-phosphate-guanosine induce therapeutic immunity against HBV infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/24308579

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA

1 reference

https://pubmed.ncbi.nlm.nih.gov/24308579

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CpG DNA rescue of murine B lymphoma cells from anti-IgM-induced growth arrest and programmed cell death is associated with increased expression of c-myc and bcl-xL.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24308579

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Do DNA vaccines induce autoimmune disease?

1 reference

https://pubmed.ncbi.nlm.nih.gov/24308579

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen

1 reference

https://pubmed.ncbi.nlm.nih.gov/24308579

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge

1 reference

https://pubmed.ncbi.nlm.nih.gov/24308579

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of bacterial DNA on cytokine production by (NZB/NZW)F1 mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/24308579

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24308579

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Suspected hepatitis B vaccination related vasculitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/24308579

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24308579

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1586/14760584.2014.863715

1 reference

Europe PubMed Central

PMC publication ID

30 June 2019

http://europepmc.org/abstract/PMC/6335645

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

30 June 2019

http://europepmc.org/abstract/PMC/6335645

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

30 June 2019

http://europepmc.org/abstract/PMC/6335645

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38168903&oldid=1745392593"